Indivior PLC (INDV)
NASDAQ: INDV · Real-Time Price · USD
9.16
+0.24 (2.69%)
Oct 29, 2024, 4:00 PM EDT - Market closed
Indivior Revenue
Indivior had revenue of $307.00M in the quarter ending September 30, 2024, with 13.28% growth. This brings the company's revenue in the last twelve months to $1.18B, up 13.44% year-over-year. In the year 2023, Indivior had annual revenue of $1.09B with 21.31% growth.
Revenue (ttm)
$1.18B
Revenue Growth
+13.44%
P/S Ratio
n/a
Revenue / Employee
$1,015,464
Employees
1,164
Market Cap
1.16B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.09B | 192.00M | 21.31% |
Dec 31, 2022 | 901.00M | 110.00M | 13.91% |
Dec 31, 2021 | 791.00M | 144.00M | 22.26% |
Dec 31, 2020 | 647.00M | -138.00M | -17.58% |
Dec 31, 2019 | 785.00M | -220.00M | -21.89% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
agilon health | 5.28B |
Guardian Pharmacy Services | 1.12B |
U.S. Physical Therapy | 621.23M |
The Pennant Group | 611.81M |
Collegium Pharmaceutical | 576.65M |
ANI Pharmaceuticals | 538.95M |
CareDx | 297.08M |
Autolus Therapeutics | 10.50M |
INDV News
- 5 days ago - Indivior PLC (INDV) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Indivior Announces Q3 2024 Financial Results - PRNewsWire
- 16 days ago - Indivior: This Value Stock Has Over 100% Upside Potential If Market Share Stabilizes In 2025 - Seeking Alpha
- 19 days ago - British drugmaker Indivior cuts 2024 revenue forecast, shares fall - Reuters
- 19 days ago - Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion - PRNewsWire
- 22 days ago - Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review - PRNewsWire
- 4 weeks ago - Indivior PLC Investors: Please contact the Portnoy Law Firm to recover your losses. October 1, 2024 Deadline to file Lead Plaintiff Motion - GlobeNewsWire
- 4 weeks ago - The Schall Law Firm Urges Shareholder Participation In A Securities Fraud Case Against Indivior PLC - Accesswire